Systematic review of 78 studies (9,195 patients with cancer): molecular tumour board-guided therapy was associated with longer progression-free survival (HR 0.73) and better response, but the overall survival effect was not significant (HR 0.87; p=0.069).
Meta-analysisn = 9,195
Russo et al. Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis